Skip to main content

Coronavirus (COVID-19) Updates: Visitation Policies (New! 11.25.20) | How We're Keeping You Safe | Latest COVID Information

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

ILYM19167, Reagan, mRNA-2752-P101, Lymphoma, mRNA-2752

Research Question:
Assess the safety and tolerability of escalating intratumoral doses of mRNA 2752 in patients with relapsed/refractory solid tumor malignancies or lymphoma.

Basic Study Information

Purpose:
The clinical study will assess the safety and tolerability of escalating intratumoral doses of mRNA 2752 in patients with relapsed/refractory solid tumor malignancies or lymphoma.

Location: University of Rochester Medical Center
Study Reference #: ILYM19167

Lead Researcher (Principal Investigator)

Lead Researcher:  Patrick Reagan

Study Contact Information

Study Coordinator: Tina Bowdish
Phone: +1 585-275-9475
Email: tina_bowdish@urmc.rochester.edu

Additional Study Details

Return to Search